comprehensive -WSS

comprehensive

author：hotspot 2025-08-26 01:32:44 - browse：289

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Inside the fall of star MIT scientist David Sabatini

WSS

Connecting traumatic brain injury and domestic violence

Was Amgen transparent enough on FDA's concern on cancer drug?

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Grail is spending more than ever lobbying Congress

AI can decode, harness the power of the humane immune system

Colorectal cancer study finds potential in overlooked immune cell

focus

comprehensive

hotspot

What does generative AI mean for health care? We asked experts

Phenylephrine and the overlooked value of the placebo effect

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Brain 'hot spot' may explain why African Americans feel greater pain

Tori Bowie and the unacceptable rates of Black maternal death

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

How to save PrEP access — and even expand it

Senate panel eyes new effort on drug shortages

Medicare details structure of new drug price negotiation program

Doctor appointment wait times are getting worse

hotspot

Histogen: Failed biotech offers rare public look inside

Chemotherapy drug shortage eases slightly but still widespread

Brain 'hot spot' may explain why African Americans feel greater pain

PhRMA sues HHS over Medicare drug price negotiation

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

What to expect at HLTH 2023, the health care industry conference

leisure time

knowledge

knowledge

Wikipedia